Back to Search Start Over

Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.

Authors :
Takamochi K
Hara K
Hayashi T
Kohsaka S
Takahashi F
Suehara Y
Shimokawa M
Suzuki K
Source :
Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2022 Jun; Vol. 168, pp. 50-58. Date of Electronic Publication: 2022 Apr 22.
Publication Year :
2022

Abstract

Objectives: Programmed death ligand 1 and 2 (PD-L1 and PD-L2) bind programmed death 1 (PD-1). PD-L1 is an established predictive biomarker of response to immunotherapies targeting PD-1 and PD-L1 in lung adenocarcinoma (LUAD). However, the clinical relevance of PD-L2 expression in patients with LUAD remains unclear; we aimed to examine this aspect using LUAD specimens.<br />Materials and Methods: PD-L2 expression status was immunohistochemically evaluated in 980 surgically resected LUAD specimens. PD-L2 expression status was classified based on the tumor proportion score (TPS) as negative (<1%), weakly positive (1-49%), or strongly positive (≥50%). Correlations between PD-L2 and PD-L1 expression status, clinicopathological features, driver oncogene alterations (EGFR, KRAS, ALK, ROS1, and RET), and prognosis were also analyzed.<br />Results: PD-L2 expression was negative in 720 (73%) of 980 LUADs, weakly positive in 190 (19%), and strongly positive in 70 (7%). The concordance rate between PD-L1 and PD-L2 expression was 60%. Male sex, smokers, tumors > 3 cm in size, high-grade tumors, tumors without EGFR mutation or ALK fusion, and tumors with KRAS mutation were more common in patients with PD-L2-positive tumors (TPS ≥ 1%) than in patients with PD-L2-negative tumors (TPS < 1%). PD-L2 expression was not associated with overall survival (OS) or relapse-free survival (RFS). However, positive PD-L2 expression tended to be associated with better OS/RFS in PD-L1-positive patients and worse OS/RFS in PD-L1-negative patients.<br />Conclusions: PD-L2-positive LUADs showed biologically aggressive characteristics. PD-L2 expression status was not associated with survival outcomes, but tended to show contrasting prognostic impacts based on PD-L1 expression status.<br /> (Copyright © 2022 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1872-8332
Volume :
168
Database :
MEDLINE
Journal :
Lung cancer (Amsterdam, Netherlands)
Publication Type :
Academic Journal
Accession number :
35489160
Full Text :
https://doi.org/10.1016/j.lungcan.2022.04.011